FDA Clears Next-Generation AI Software for Portable Brain MRI
The Optive AI software, the tenth software release for the Swoop portable MRI system, reportedly offers enhanced clarity and anatomical detail for ultra-low-field MRI of the brain.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the Optive AI software, which may significantly elevate the quality of ultra-low-field brain MRI scans.
The tenth software release for the Swoop portable MRI system, the Optive AI software utilizes advanced algorithms to bolster noise cancellation, image reconstruction and post-processing, according to Hyperfine, the developer of the Swoop MRI platform.
The newly FDA-cleared Optive AI software (see MRI scan on the right) enhances the clarity and anatomical details of ultra-low-field MRI scans obtained with the Swoop portable MRI system, according to Hyperfine, the manufacturer of the Swoop system. (Images courtesy of Hyperfine.)
Hyperfine noted that use of the Optive AI software allows for sharper clarity and anatomical detail across all sequences obtained with ultra-low-field brain MRI.
“The advanced AI algorithms integrated into our new software platform dramatically elevate image quality at ultra-low field strength, enabling more confident diagnoses at the point of care,” noted Rafael O’Halloran, the vice president of technology at Hyperfine.
The company said the Optive AI software will be available in the third quarter of 2025.
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.
